Literature DB >> 6344800

Cutaneous histiocytosis X. The presence of S-100 protein and its use in diagnosis.

G Rowden, E M Connelly, R K Winkelmann.   

Abstract

The cellular localization of glial S-100 protein was investigated in paraffin-embedded sections of cutaneous histiocytosis X and in a variety of cutaneous infiltrative disorders, including juvenile xanthogranuloma, necrobiotic xanthogranuloma, papular xanthoma, eruptive histiocytoma, and reticulohistiocytosis. Immunoperoxidase staining with a rabbit anti-calf brain-S-100 antibody demonstrated strong and consistent activity in atypical histiocytes in all histiocytosis X specimens. No detectable S-100 protein was demonstrated in either histiocytes or giant cells in the non-X histiocytic disorders investigated. Positive controls were included within both groups of disorders in respect to melanocyte, epidermal Langerhans' cell, and dermal Schwann's cell staining. These findings are interpreted as evidence for diversity in the mononuclear phagocyte system and demonstrate the practicality of such a simple test in diagnostic problems involving infiltrative histiocytic disorders of the skin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344800     DOI: 10.1001/archderm.119.7.553

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  Gastric polyposis caused by multifocal histiocytosis X.

Authors:  R Wada; S Yagihashi; R Konta; T Ueda; T Izumiyama
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  One half of the CD11b+ human peripheral blood T lymphocytes coexpresses the S-100 protein.

Authors:  C Ferrari; P Sansoni; G Rowden; G C Manara; C Torresani; G De Panfilis
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

3.  An immunoperoxidase study of S-100 protein, lysozyme and NCA protein distribution in histiocytosis X and allied disorders.

Authors:  T Morishima; T Shimura; M Higaki; T Ochiai; S Watanabe
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

4.  Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions.

Authors:  R M Mackie; I Campbell; M L Turbitt
Journal:  J Clin Pathol       Date:  1984-04       Impact factor: 3.411

5.  Production and characterization of monoclonal antibodies with specificity for the S100 beta polypeptide of brain S100 fractions.

Authors:  L J Van Eldik; B Ehrenfried; R A Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.